PedAM
Pediatric Disease Annotations & Medicines
| Disease | splenomegaly |
| Phenotype | C0001815|myelofibrosis |
| Sentences | 12 |
| PubMedID- 23117264 | Although allogeneic hematopoietic stem cell transplantation (hsct) is currently the only curative strategy for both conditions, massive splenomegaly frequently observed in patients with myelofibrosis is considered to be a risk factor for graft failure or engraftment delay after transplantation. |
| PubMedID- 26357842 | Clinically, the presence of myelofibrosis is associated with splenomegaly, peripheral blood cytopaenias and constitutional symptoms including fatigue, night sweats and fever [3, 10, 11]. |
| PubMedID- 24403262 | Symptom burden and splenomegaly in patients with myelofibrosis in the united states: a retrospective medical record review. |
| PubMedID- 24800261 | This disease has serious consequences since it may progress towards myelofibrosis with splenomegaly, or indeed leukaemia. |
| PubMedID- 26167286 | This novel inhibitor of janus kinases 1 and 2 has shown promising effects in reducing constitutional symptoms and splenomegaly in patients with myelofibrosis and more recently was also shown to increase overall survival [1, 2]. |
| PubMedID- 23704469 | Although reduction of splenomegaly in myelofibrosis patients is the anticipated benefit of ruxolitinib, the drug may also have the potential to improve leukopaenia if used at a low dose. |
| PubMedID- 24237791 | We used this short lapse of time based on the observation that first effects of ruxolitinib on symptoms and splenomegaly in patients with myelofibrosis can be appreciated as early as at 2–4 weeks of treatment. |
| PubMedID- 22852872 | splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of janus kinase 2 inhibitors. |
| PubMedID- 22403733 | Several studies have shown that small molecule jak2-inhibitors affect growth and viability of the neoplastic cells but also possess potent anti-inflammatory effects and display remarkable resolution of hypermetabolic symptoms in concert with reduction of splenomegaly in patients with myelofibrosis (mf) [7]–[13]. |
| PubMedID- 25897239 | While both thalidomide and lenalidomide offered improvements in anemia and splenomegaly for patients with myelofibrosis, their therapeutic application was limited by rates of neuropathy and myelosuppression. |
| PubMedID- 25282037 | Excluded were cases with atypical megakaryocytes, dysplasia, basophilia, osteosclerosis, unexplained splenomegaly, or neoplasms associated with myelofibrosis (mf). |
| PubMedID- 21415968 | How to face massive splenomegaly in myelofibrosis: splenomegaly can be found in all the mpns, but it is a main complaint of patients with myelofibrosis as the manifestation of massive extramedullary hematopoiesis that results largely from the substitution of hematopoietic tissue with reticulin and collagen fibers in the bone marrow. |
Page: 1